Cargando…

Multiple Brain Pseudoprogression in a Patient With NSCLC Treated With Pembrolizumab

Detalles Bibliográficos
Autores principales:	Moliner, Laura, Capellades, Jaume, Taus, Álvaro, Arriola, Edurne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474293/ https://www.ncbi.nlm.nih.gov/pubmed/34589952 http://dx.doi.org/10.1016/j.jtocrr.2020.100070

Ejemplares similares

Multiple oligodendroglioma with pseudoprogression
por: Matsuyama, Junko
Publicado: (2012)

Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC
por: Rocha, Pedro, et al.
Publicado: (2020)

Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
por: Kageyama, Takumi, et al.
Publicado: (2022)

EGFR-Mutant Lung Adenocarcinoma Mimicking a Pneumonia
por: Taus, Álvaro, et al.
Publicado: (2012)

Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
por: Trabjerg, Natacha Dencker, et al.
Publicado: (2019)

An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient
por: Krukowska, Kinga, et al.
Publicado: (2020)

Pseudoprogression as an adverse event of glioblastoma therapy
por: Balaña, Carmen, et al.
Publicado: (2017)

Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma
por: Karydis, Ioannis, et al.
Publicado: (2016)

Pseudoprogression of brain tumors
por: Thust, Stefanie C., et al.
Publicado: (2018)

Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression
por: Grierson, Patrick, et al.
Publicado: (2017)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Watanabe, Yukinobu, et al.
Publicado: (2021)

Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment
por: Melian, Marcos, et al.
Publicado: (2018)

Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
por: Garcia, Diogo, et al.
Publicado: (2021)

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report
por: Ozaki, Yukinori, et al.
Publicado: (2017)

Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report
por: Riudavets, Mariona, et al.
Publicado: (2022)

Pseudoprogression in lung cancer: a case report
por: Meoni, Giulia, et al.
Publicado: (2020)

Rapid Onset of Takotsubo Cardiomyopathy Induced by an Infusion Reaction to Pembrolizumab in a Patient with NSCLC
por: Okamatsu, Yuki, et al.
Publicado: (2020)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer
por: Suyanto, Suyanto, et al.
Publicado: (2019)

Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge
por: Ríos-Hoyo, Alejandro, et al.
Publicado: (2022)

Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report
por: Gonugunta, Amrit S., et al.
Publicado: (2022)

Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
por: Huang, Weiwei, et al.
Publicado: (2020)

A case of pseudoprogression in avelumab maintenance therapy for metastatic bladder cancer
por: Hayakawa, Nozomi, et al.
Publicado: (2022)

Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma
por: Ikeda, Takaya, et al.
Publicado: (2018)

MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)
por: Casadevall, David, et al.
Publicado: (2015)

Pseudoprogression and Immunotherapy Phenomena
por: Waxman, Elizabeth S., et al.
Publicado: (2020)

Case Report: Transformation From Cold to Hot Tumor in a Case of NSCLC Neoadjuvant Immunochemotherapy Pseudoprogression
por: Jia, Wenxiao, et al.
Publicado: (2021)

Pseudoprogression Disease in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy
por: Zhu, Wanshan, et al.
Publicado: (2023)

Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination
por: van der Woude, Lieke L, et al.
Publicado: (2022)

Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab
por: Zibelman, Matthew, et al.
Publicado: (2016)

Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma
por: Zibetti Dal Molin, Graziela, et al.
Publicado: (2018)

Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma
por: McNally, Michelle A., et al.
Publicado: (2021)

Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma
por: Oliveira, Leandro J. C., et al.
Publicado: (2018)

Pseudoprogression of Malignant Peripheral Nerve Sheath Tumor in Patient with Neurofibromatosis Type 1, a Case Report
por: Lessing, Andrés J., et al.
Publicado: (2021)

Late tumor pseudoprogression followed by complete remission after lung stereotactic ablative radiotherapy
por: Stauder, Michael C, et al.
Publicado: (2013)

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
por: Sweis, Randy F., et al.
Publicado: (2018)

Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report
por: Kuge, Tomoki, et al.
Publicado: (2021)

The Diagnosis and Treatment of Pseudoprogression, Radiation Necrosis and Brain Tumor Recurrence
por: Parvez, Kashif, et al.
Publicado: (2014)

Pseudoprogression in low-grade glioma
por: Slater, Jason M., et al.
Publicado: (2019)

Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab
por: Sánchez-Gastaldo, Amparo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pd3ri4hn77tg9qib3bq6olg421